Ras inhibition increases the frequency and function of regulatory T cells and attenuates type-1 diabetes in non-obese diabetic mice

European Journal of Pharmacology

Volumn 616, Issue 1-3, 2009, Pages 301-305

  Mor, Adi ^a   Kloog, Yoel ^a   Keren, Gad ^b   George, Jacob ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Diabetes; Foxp3; Non obese diabetic (NOD) mouse; Ras; Regulatory T cell

Indexed keywords

5 FLUORO FARNESYLTHIOSALICYLIC ACID; ANTIDIABETIC AGENT; CYTOKINE; FARNESYLTHIOSALICYLIC ACID; GUANOSINE TRIPHOSPHATE; INSULIN; RAS PROTEIN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE;

ANIMALS; DIABETES MELLITUS, TYPE 1; ENZYME INHIBITORS; FARNESOL; FORKHEAD TRANSCRIPTION FACTORS; HOMEOSTASIS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MICE; MICE, INBRED NOD; PROTO-ONCOGENE PROTEINS P21(RAS); SALICYLIC ACIDS; T-LYMPHOCYTES, REGULATORY; UP-REGULATION;

EID: 67651099098     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.06.001     Document Type: Article

References (19)

1. Aharonson Z., Gana-Weisz M., Varsano T., Haklai R., Marciano D., and Kloog Y. Stringent structural requirements for anti-Ras activity of S-prenyl analogues. Biochim. Biophys. Acta 1406 (1998) 40-50
2. Anderson M.S., and Bluestone J.A. The NOD mouse: a model of immune dysregulation. Annu. Rev. Immunol. 23 (2005) 447-485
3. Brusko T., and Bluestone J. Clinical application of regulatory T cells for treatment of type 1 diabetes and transplantation. Eur. J. Immunol. 38 (2008) 931-934
4. Chen Z., Herman A.E., Matos M., Mathis D., and Benoist C. Where CD4 + CD25+ T reg cells impinge on autoimmune diabetes. J. Exp. Med. 202 (2005) 1387-1397
5. D'Alise A.M., Auyeung V., Feuerer M., Nishio J., Fontenot J., Benoist C., and Mathis D. The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 19857-19862
6. Durinovic-Bello I. Autoimmune diabetes: the role of T cells, MHC molecules and autoantigens. Autoimmunity 27 (1998) 159-177
7. Eisenberg S., and Henis Y.I. Interactions of Ras proteins with the plasma membrane and their roles in signaling. Cell. Signal. 20 (2008) 31-39
8. Goldberg L., and Kloog Y. A Ras inhibitor tilts the balance between Rac and Rho and blocks PI3-kinase-dependent glioblastoma cell migration. Cancer Res. 66 (2006) 11709-11717
9. Green E.A., Gorelik L., McGregor C.M., Tran E.H., and Flavell R.A. CD4 + CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-beta-TGF-beta receptor interactions in type 1 diabetes. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 10878-10883
10. Herman A.E., Freeman G.J., Mathis D., and Benoist C. CD4 + CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J. Exp. Med. 199 (2004) 1479-1489
11. Mellanby R.J., Thomas D., Phillips J.M., and Cooke A. Diabetes in non-obese diabetic mice is not associated with quantitative changes in CD4+ CD25+ Foxp3+ regulatory T cells. Immunology 121 (2007) 15-28
12. Mor A., Keren G., Kloog Y., and George J. N-Ras or K-Ras inhibition increases the number and enhances the function of Foxp3 regulatory T cells. Eur. J. Immunol. 38 (2008) 1493-1502
13. Rotblat B., Ehrlich M., Haklai R., and Kloog Y. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer. Methods Enzymol. 439 (2008) 467-489
14. Sakaguchi S., Yamaguchi T., Nomura T., and Ono M. Regulatory T cells and immune tolerance. Cell 133 (2008) 775-787
15. Salomon B., Lenschow D.J., Rhee L., Ashourian N., Singh B., Sharpe A., and Bluestone J.A. B7/CD28 costimulation is essential for the homeostasis of the CD4 + CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12 (2000) 431-440
16. Santamaria P. Effector lymphocytes in islet cell autoimmunity. Rev. Endocr. Metab. Disord. 4 (2003) 271-280
17. Tang Q., Henriksen K.J., Boden E.K., Tooley A.J., Ye J., Subudhi S.K., Zheng X.X., Strom T.B., and Bluestone J.A. Cutting edge: CD28 controls peripheral homeostasis of CD4 + CD25+ regulatory T cells. J. Immunol. 171 (2003) 3348-3352
18. Tritt M., Sgouroudis E., d Hennezel E., Albanese A., and Piccirillo C.A. Functional waning of naturally occurring CD4+ regulatory T-cells contributes to the onset of autoimmune diabetes. Diabetes 57 (2008) 113-123
19. Yoon J.W., and Jun H.S. Autoimmune destruction of pancreatic beta cells. Am. J. Ther. 12 (2005) 580-591